{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T20:15:15Z","timestamp":1777320915213,"version":"3.51.4"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007697","name":"Northern Advancement Center for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007697","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.antiviral.2020.104932","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T11:28:53Z","timestamp":1600169333000},"page":"104932","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A biaryl sulfonamide derivative as a novel inhibitor of filovirus infection"],"prefix":"10.1016","volume":"183","author":[{"given":"Mao","family":"Isono","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wakako","family":"Furuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunari","family":"Kondoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Kajihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashid","family":"Manzoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Okuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9448-8227","authenticated-orcid":false,"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0186-9587","authenticated-orcid":false,"given":"Andrea","family":"Marzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Sakaitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8764-1350","authenticated-orcid":false,"given":"Asuka","family":"Nanbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayato","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104932_bib1","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1128\/JVI.76.13.6841-6844.2002","article-title":"C-type lectins DC-SIGN and L-SIGN mediate cellular entry by ebola virus in cis and in trans","volume":"76","author":"Alvarez","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104932_bib2","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and virological characteristics of ebola virus disease patients treated with favipiravir (T-705) - Sierra Leone, 2014","volume":"63","author":"Bai","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104932_bib3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The pathogenesis of ebola virus disease","volume":"12","author":"Baseler","year":"2017","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.antiviral.2020.104932_bib4","doi-asserted-by":"crossref","first-page":"12289","DOI":"10.1073\/pnas.220398297","article-title":"The Ebola virus VP35 protein functions as a type I IFN antagonist","volume":"97","author":"Basler","year":"2000","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.antiviral.2020.104932_bib5","doi-asserted-by":"crossref","first-page":"S528","DOI":"10.1093\/infdis\/jiy333","article-title":"Vaccine generation of protective ebola antibodies and identification of conserved B-cell signatures","volume":"218","author":"Cagigi","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104932_bib6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.coph.2016.08.016","article-title":"Antiviral therapeutics for the treatment of Ebola virus infection","volume":"30","author":"Cardile","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2020.104932_bib7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature10348","article-title":"Ebola virus entry requires the cholesterol transporter Niemann-Pick C1","volume":"477","author":"Carette","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2020.104932_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature10380","article-title":"Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection","volume":"477","author":"C\u00f4t\u00e9","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2020.104932_bib9","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1086\/520590","article-title":"In vitro and in vivo characterization of recombinant ebola viruses expressing enhanced green fluorescent protein","volume":"196","author":"Ebihara","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104932_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/bs.aivir.2017.12.002","article-title":"Filoviruses: ecology, molecular biology, and evolution","volume":"100","author":"Emanuel","year":"2018","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.antiviral.2020.104932_bib11","doi-asserted-by":"crossref","first-page":"20514","DOI":"10.1038\/srep20514","article-title":"Discovery of an antibody for pan-ebolavirus therapy","volume":"6","author":"Furuyama","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2020.104932_bib12","series-title":"Quantification of Filovirus Glycoprotein-specific Antibodies","first-page":"309","author":"Furuyama","year":"2017"},{"key":"10.1016\/j.antiviral.2020.104932_bib13","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","article-title":"Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study","volume":"375","author":"Geisbert","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2020.104932_bib14","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41564-018-0227-2","article-title":"The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses","volume":"3","author":"Goldstein","year":"2018","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.antiviral.2020.104932_bib15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/v4020258","article-title":"Filovirus entry: a novelty in the viral fusion world","volume":"4","author":"Hunt","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2020.104932_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.virusres.2004.08.014","article-title":"Filovirus budding","volume":"106","author":"Jasenosky","year":"2004","journal-title":"Virus Res."},{"key":"10.1016\/j.antiviral.2020.104932_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa5597","article-title":"A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity","volume":"7","author":"Johansen","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.antiviral.2020.104932_bib18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.coi.2018.05.001","article-title":"The structural basis for filovirus neutralization by monoclonal antibodies","volume":"53","author":"King","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.antiviral.2020.104932_bib19","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1093\/infdis\/jiy248","article-title":"Single-nucleotide polymorphisms in human NPC1 influence filovirus entry into cells","volume":"218","author":"Kondoh","year":"2018","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104932_bib20","doi-asserted-by":"crossref","first-page":"8426","DOI":"10.1073\/pnas.1019030108","article-title":"T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus","volume":"108","author":"Kondratowicz","year":"2011","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.antiviral.2020.104932_bib21","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1128\/JVI.03156-14","article-title":"Interaction between TIM-1 and NPC1 is important for cellular entry of ebola virus","volume":"89","author":"Kuroda","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104932_bib22","first-page":"1","article-title":"Medical countermeasures during the 2018 ebola virus disease outbreak in the North kivu and ituri provinces of the democratic republic of the Congo: a rapid genomic assessment","volume":"3099","author":"Mbala-Kingebeni","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104932_bib23","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1038\/emboj.2012.53","article-title":"Ebola virus entry requires the host-programmed recognition of an intracellular receptor","volume":"31","author":"Miller","year":"2012","journal-title":"EMBO J."},{"issue":"80","key":"10.1016\/j.antiviral.2020.104932_bib24","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"Misasi","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.antiviral.2020.104932_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jir334","article-title":"Antibody-dependent enhancement of marburg virus infection","volume":"204","author":"Nakayama","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104932_bib26","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(18)33011-3","article-title":"Randomised controlled trial begins for Ebola therapeutics","volume":"392","author":"Nakkazi","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.antiviral.2020.104932_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001121","article-title":"Ebolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent manner","volume":"6","author":"Nanbo","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2020.104932_bib28","series-title":"Clinical Trial of Investigational Ebola Treatments Begins in the Democratic Republic of the Congo | NIH","author":"NIH","year":"2019"},{"key":"10.1016\/j.antiviral.2020.104932_bib29","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1128\/JVI.76.10.4855-4865.2002","article-title":"Ebola virus VP40 drives the formation of virus-like filamentous particles along with GP","volume":"76","author":"Noda","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104932_bib30","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1021\/acs.jmedchem.7b01249","article-title":"Target identification and mode of action of four chemically divergent drugs against ebolavirus infection","volume":"61","author":"Ren","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2020.104932_bib31","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1086\/514303","article-title":"Ebola (subtype Reston) virus among quarantined nonhuman primates recently imported from the Philippines to the United States","volume":"179","author":"Rollin","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104932_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001110","article-title":"Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes","volume":"6","author":"Saeed","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2020.104932_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1099\/jgv.0.001170","article-title":"ICTV virus taxonomy profile: Nodaviridae","volume":"100","author":"Sahul Hameed","year":"2019","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2020.104932_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1007427","article-title":"IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody","volume":"15","author":"Saito","year":"2019","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2020.104932_bib35","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/v11030274","article-title":"Ebola virus entry: from molecular characterization to drug discovery","volume":"11","author":"Salata","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2020.104932_bib36","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1128\/JVI.80.8.4174-4178.2006","article-title":"Role of endosomal cathepsins in entry mediated by the ebola virus glycoprotein","volume":"80","author":"Schornberg","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104932_bib37","article-title":"Structure-based in silico screening identifies a potent ebolavirus inhibitor from a traditional Chinese medicine library","author":"Shaikh","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2020.104932_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/76780c06-ac81-48a3-8cce-509da6858fe5","article-title":"Multiple cationic amphiphiles induce a niemann-pick C phenotype and inhibit ebola virus entry and infection","volume":"8","author":"Shoemaker","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2020.104932_bib39","first-page":"1","article-title":"Experimental treatment with favipiravir for ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.antiviral.2020.104932_bib40","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1128\/JVI.77.2.1069-1074.2003","article-title":"Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses","volume":"77","author":"Takada","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104932_bib41","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1128\/JVI.78.6.2943-2947.2004","article-title":"Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry","volume":"78","author":"Takada","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2020.104932_bib42","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1073\/pnas.94.26.14764","article-title":"A system for functional analysis of Ebola virus glycoprotein","volume":"94","author":"Takada","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2020.104932_bib43","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1073\/pnas.1712263115","article-title":"Ebola virus proteins NP, VP35, and VP24 are essential and sufficient to mediate nucleocapsid transport","volume":"115","author":"Takamatsu","year":"2018","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.antiviral.2020.104932_bib44","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.epidem.2019.01.003","article-title":"Assessing reporting delays and the effective reproduction number: the Ebola epidemic in DRC, May 2018\u2013January 2019","volume":"26","author":"Tariq","year":"2019","journal-title":"Epidemics"},{"key":"10.1016\/j.antiviral.2020.104932_bib45","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1604330","article-title":"A randomized, controlled trial of ZMapp for ebola virus infection","volume":"375","author":"The PREVAIL II Writing Group","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104932_bib46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","article-title":"Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning","volume":"329","author":"Tiller","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.antiviral.2020.104932_bib47","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.2202","article-title":"Advanced antisense therapies for postexposure protection against lethal filovirus infections","volume":"16","author":"Warren","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2020.104932_bib48","series-title":"Ebola | Ebola Situation Reports: Democratic Republic of the Congo","author":"WHO","year":"2019"},{"key":"10.1016\/j.antiviral.2020.104932_bib49","series-title":"Ebola | Ebola Treatments Approved for Compassionate Use in Current Outbreak","author":"WHO","year":"2018"},{"key":"10.1016\/j.antiviral.2020.104932_bib50","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4161\/viru.21302","article-title":"The ebolavirus VP24 interferon antagonist: know your enemy","volume":"3","author":"Zhang","year":"2012","journal-title":"Virulence"},{"key":"10.1016\/j.antiviral.2020.104932_bib51","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1021\/acs.jmedchem.8b00350","article-title":"Structures of ebola virus glycoprotein complexes with tricyclic antidepressant and antipsychotic drugs","volume":"61","author":"Zhao","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2020.104932_bib52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nature18615","article-title":"Toremifene interacts with and destabilizes the Ebola virus glycoprotein","volume":"535","author":"Zhao","year":"2016","journal-title":"Nature"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220303466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220303466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:32:21Z","timestamp":1759062741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220303466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":52,"alternative-id":["S0166354220303466"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104932","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A biaryl sulfonamide derivative as a novel inhibitor of filovirus infection","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104932","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104932"}}